Pharmaco - Press Releases

Date	Title	Company
07-Dec-2020	Karyopharm Announces Presentation of New XPOVIO® (Selinexor) Data in Patients with Acute Myeloid Leukemia at the American Society of Hematology 2020 Annual Meeting	Karyopharm Therapeutics Inc.
07-Dec-2020	Data Evaluating Tafasitamab with and without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented at ASH 2020	MorphoSys AG
07-Dec-2020	Exclusive interview with Séverine Duband, Nemera released ahead of Pre-filled Syringes Europe	SMi Group Ltd
07-Dec-2020	Original-Research: MPH Health Care AG (von First Berlin Equity Research GmbH)	MPH Health Care AG
07-Dec-2020	Slayback Pharma Appoints Dr Sumitra Pillai as Head of R&D	Slayback Pharma LLC
07-Dec-2020	INOVIO Doses First Subject in Phase 2 Segment of its INNOVATE Phase 2/3 Clinical Trial for INO-4800, its DNA Medicine to Prevent COVID-19	INOVIO Pharmaceuticals, Inc.
07-Dec-2020	Seqirus Presents New Late-Breaking Data at ESWI 2020 Highlighting Benefits of MF59®-Adjuvanted Seasonal Influenza Vaccine	Seqirus
07-Dec-2020	PharmAbcine to present new interim data from its ongoing mTNBC trial at SABCS 2020	PharmAbcine
07-Dec-2020	Blueprint Medicines Data Presented at 62nd ASH Annual Meeting and Exposition Highlight Broad Commitment to Advance Patient Care in Systemic Mastocytosis	Blueprint Medicines Corporation
07-Dec-2020	Alcresta Therapeutics Appoints Alan Muney, MD To Board Of Directors	Alcresta Therapeutics, Inc.
07-Dec-2020	Watson-Marlow pump equips tablet-coating turbine at Bailly Creat	Sciad Newswire
07-Dec-2020	Relief Therapeutics and NeuroRx Meet 165 Patient Enrollment Target in Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure	RELIEF THERAPEUTICS Holdings AG
07-Dec-2020	KaliVir Immunotherapeutics and Astellas Enter Worldwide Exclusive Licensing Agreement for Development and Commercialization of VET2-L2 Novel Oncolytic Virus	KaliVir Immunotherapeutics
07-Dec-2020	Roivant Unveils Targeted Protein Degradation Platform	Roivant Sciences
07-Dec-2020	Antengene Announces Acceptance of IND Application in China for ATG-010 (selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study	Antengene Corporation Limited
06-Dec-2020	MAGROLIMAB DEMONSTRATES CLINICAL RESPONSES IN ONGOING PHASE 1B TRIAL OF PREVIOUSLY UNTREATED ACUTE MYELOID LEUKAEMIA PATIENTS	Gilead Sciences, Inc.
06-Dec-2020	NEW FOUR-YEAR DATA SHOW LONG-TERM SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA TREATED WITH YESCARTA® (AXICABTAGENE CILOLEUCEL) IN ZUMA-1 TRIAL	Kite, A Gilead Company
06-Dec-2020	YESCARTA® (AXICABTAGENE CILOLEUCEL) IS FIRST CAR T CELL THERAPY TO DEMONSTRATE HIGH RESPONSE RATES AND DURABLE CLINICAL BENEFIT IN A PIVOTAL INDOLENT NON-HODGKIN LYMPHOMA STUDY	Kite, A Gilead Company
06-Dec-2020	Syndax Pharmaceuticals Announces Additional Positive Data from Phase 1 Trial of Axatilimab in Patients with cGVHD	Syndax Pharmaceuticals, Inc.
06-Dec-2020	CTI BioPharma Announces Presentation of Data Supporting Pacritinib's Potential Benefit in Preventing Acute GVHD at the 62nd American Society of Hematology Meeting	CTI BioPharma Corp.